Intervention News

SAN FRANCISCO — Data show a novel transcatheter mitral valve edge-to-edge repair system was associated with a sustained reduction in mitral regurgitation plus functional and quality-of-life gains for patients at prohibitive surgical risk.

SAN FRANCISCO — Transcatheter tricuspid valve replacement was feasible and had a lower-than-expected rate of safety events, according to an analysis of the first 150 patients in the TRISCEND II pivotal trial.

SAN FRANCISCO — A biodegradable polymer sirolimus-eluting stent remained superior to a durable polymer everolimus-eluting stent for treating STEMI at 5 years, a difference driven by lower rates of ischemia-driven repeat revascularizations.

SAN FRANCISCO — In a real-world population of patients with ACS or chronic coronary syndrome, a strategy guided by instantaneous wave-free ratio was similarly safe as one guided by fractional flow reserve at 5 years, data show.

SAN FRANCISCO — A paclitaxel-coated balloon was superior to conventional balloon angioplasty for treatment of coronary in-stent restenosis, according to the results of the AGENT IDE trial presented at TCT 2023.

SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with 12 months of dual antiplatelet therapy.

SAN FRANCISCO — An everolimus-eluting bioresorbable scaffold was superior to angioplasty for the treatment of patients with chronic limb-threatening ischemia, according to the results of the LIFE-BTK trial presented at TCT 2023.

SAN FRANCISCO — In a pooled analysis, transcatheter edge-to-edge repair benefited patients with severe tricuspid regurgitation, even those with complex anatomies.

SAN FRANCISCO — One-year data from the SWISS-APERO study show similar clinical outcomes and rates of patent left atrial appendages for patients undergoing LAA closure with either the Amulet or Watchman FLX devices, a speaker reported.

SAN FRANCISCO — A fourth-generation mitral valve transcatheter edge-to-edge repair system was associated with durable reduction in mitral regurgitation severity to mild or less for most patients, including those with complex anatomy.